Swiss secondary gives lifeblood to market

Actelion, the Swiss biopharmaceuticals company, gave the new issue market a welcome shot in the arm today with its successful Sfr410m (€272m) secondary sale, which was increased on the back of strong demand and priced at a very tight discount.

In the sale led by Credit Suisse First Boston, Actelion increased the number of shares on offer by 15% from 435,000 to 500,000 on the back of strong demand, with an addition 70,000 shares on offer in the greenshoe.

WSJ Logo
Europe Draws Up Retaliatory Tariffs for U.S. Goods in Case No Trade Deal Is ReachedExternal link

Europe Draws Up Retaliatory Tariffs for U.S. Goods in Case No Trade Deal Is Reached